CClinicalTrials.gg
CompletedNCT03288142iSmartHypUpdated Apr 15, 2022Results posted

The Smart Hypertension Control Study

An interventional study of Hypertension Coaching Application and Home Monitor and Control: Tracking Application and Home Monitor in Hypertension, sponsored by Northwestern University. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-04-15.

Sponsored by Northwestern University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
333
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Investigators at Northwestern University will partner with Omron Healthcare Co., Ltd. (hereinafter referred to as "Omron") to conduct a randomized controlled trial of a hypertension personal control program (HPCP), known as Lark HTN Pro with a home blood pressure monitoring device (HBMD) compared to a HBMD alone. The overarching goal of this study is to investigate the effects of the HPCP on blood pressure, blood pressure self-management behaviors, and healthy lifestyle behaviors among adults with hypertension.

Read the detailed description

The study team used structured language queries of electronic health record data from the Northwestern Medicine Enterprise Data Warehouse (NMEDW) to identify potentially-eligible participants with elevated blood pressure and exclude patients with clinical exclusion criteria from Northwestern Medical Group outpatient practices. During the on-site visit individuals were asked to provide written informed consent and have blood pressure measured in a standardized fashion to see if this inclusion criteria is met.

We conducted a non-blinded randomized controlled trial among hypertensive adults in NMG outpatient clinics. We randomized participants in a 1:1 fashion to the intervention group (HPCP + HBMD) or the comparator group (HBMD alone). Randomization was performed using a centralized computer-generated assignment sequence uploaded a priori to Northwestern University's REDCap (Research Electronic Data Capture) application. Randomization was stratified by: age (\<65 or ≥65 years of age) and baseline systolic blood pressure (\<145 or ≥145 mmHg) to optimize the likelihood of obtaining similar populations in each treatment group.

We recruited adults with elevated blood pressure as assessed by in-person standardized examination at baseline. We measured change in blood pressure by in-person examination at 6 months. We recruited between 350 to 400 participants in order to have 333 participants with analyzable data at the time of study completion. If changes were deemed necessary, a revision to the study protocol was submitted to the IRB for review and approval prior to implementing these changes.

Control group participants were provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participant also received an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants were instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants continued to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.

The intervention group received all the interventions provided to the control group. Intervention group participants were sent a hyperlink to install the hypertension personal control program (HPCP) ("Lark HTN Pro"), which is a smartphone application installed on their iOS device during their initial office visit (screening/baseline) and successfully took a reading from their HBMD. The HPCP has blood pressure, medication, and weight monitoring, including periodic reminders for the user to measure blood pressure, measure weight, and take their medication(s). The HPCP provides real-time feedback based on user input, such as out-of-range measurements and has additional features designed to encourage behavior change in areas such as dietary intake, physical activity, sleep, and stress reduction.

Study participants were required to return for a 6-month study visit (within 2 weeks before to 4 weeks after). During the 6-month visit, subjects had their height/weight and blood pressure measured again. Participants also repeated questionnaires related to their current cardiovascular medications. They also completed questionnaires measuring: medication adherence, self-efficacy, diet, physical activity, and sleep duration. An exit survey was provided to participants at the end of the 6-month follow up visit to obtain feedback on Lark and Omron apps usability.

02

Conditions studied

  • Hypertension

Browse trials for

03

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged 18 years to \<85 years at the time of screening
  • Standardized mean blood pressure measurement ≥135 to \<180 mmHg systolic or ≥85 to \<110 mmHg diastolic
  • Have and use an iOS device(s) (iPhone generation 5s or newer)
  • Able to provide written informed consent prior to participation in the study
  • Receive their primary care from a Northwestern Medicine clinic site

Exclusion criteria

Exclusion Criteria:

  • Current user of the HCPC (Lark HTN Pro)
  • Standardized mean blood pressure measurement ≥180 mmHg systolic or ≥110 mmHg diastolic
  • Persistent atrial fibrillation as indicated in the electronic health record (EHR)
  • Pregnant or planning to become pregnant during the study period
  • Severe kidney disease, defined as estimated glomerular filtration rate \<30 per 1.73 m2 or currently on renal replacement therapy (i.e. hemodialysis or peritoneal dialysis)
  • Hearing impaired and unable to respond to phone calls
  • Lack of fluency in English
  • History of a cardiovascular event (stroke, transient ischemic attack, myocardial infarction, coronary artery bypass grafting) in the past 3 months
  • Diagnosis of dementia as indicated in the electronic health record
  • Diagnosis of psychosis as indicated in the electronic health record
  • Terminal cancer diagnosis or NYHA III or IV heart failure
  • Deemed unsuitable for study by primary care provider
  • Individuals requiring BP monitor cuff size larger than 17 inches or 42cm
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
333 participants (actual)

Study arms

  • Experimental
    Intervention: Hypertension Coaching Application and Home Monitor:

    The intervention group will receive all the interventions provided to the control group. In addition, intervention group participants will install on their mobile phone the hypertension personal control program (HPCP) ("Lark HTN Pro"), which is a smartphone application. The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD. The HPCP has blood pressure, medication, and weight monitoring, including periodic reminders for the user to measure blood pressure, measure weight, and take their medication(s). The HPCP provides real-time feedback based on user input, such as out-of-range measurements and has additional features designed to encourage behavior change in areas such as dietary intake, physical activity, sleep, and stress reduction. Users can set goals and receive guidance and feedback through the app.

    Other: Hypertension Coaching Application and Home Monitor

  • Active comparator
    Control:Tracking Application and Home Monitor:

    Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.

    Other: Control: Tracking Application and Home Monitor

Interventions

  • OtherHypertension Coaching Application and Home Monitor

    The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD

    Also known as: Lark HTN Pro

  • OtherControl: Tracking Application and Home Monitor

    Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.

05

What researchers measure

Primary outcomes

  1. Blood Pressure at 6 Months

    Time frame: 6 months

  2. Blood Pressure <140/90mmHg

    Time frame: 6 months

Secondary outcomes

  1. Number of Antihypertensive Agents Used

    Number of self reported antihypertensive medication drug classes taken

    Time frame: 6 months

  2. Antihypertensive Medication Intensification, No. of Additions, Dose Increases, or Substitutions

    Number of antihypertensive drug classes that were increased, added or substituted for another drug class

    Time frame: 6 months

  3. Number of Health System Contacts (Telephone, Office, or Mychart Encounters)

    Time frame: 6 months

  4. Frequency of Home Blood Pressure Measurements Per Month

    Frequency of home blood pressure measurements per month derived from home blood pressure monitor for months when home monitoring occurred

    Time frame: 6 months

  5. Months When a Home Blood Pressure Reading is Obtained, No.

    Number of months out of the 6 month study period when at least one home blood pressure reading was obtained

    Time frame: 6 months

  6. Self-efficacy: Confidence in Controlling High Blood Pressure

    Self reported response to :How confident are you that you will be able to get your blood pressure controlled and keep it there during the next few months? Reponses were on a 5-point scale ranging from (1) not at all confident to (5) extremely confident.

    Time frame: 6 months

  7. BMI

    Body mass index is calculated as the weight in kilograms divided by height in meters squared.

    Time frame: 6 months

  8. Diet Quality Score (as Assessed by Dietary Approaches to Stop Hypertension Questionnaire, DASH-Q

    Sum of responses represents intake of foods associated with the Dietary Approaches to Stop Hypertension diet. Range is from 0 to 77 with a higher score indicating better diet. Scores 32 and below indicate a low-quality diet, scores 33 to 51 indicate a medium-quality diet, and scores greater than or equal to 52 indicate a high-quality diet.

    Time frame: 6 months

  9. Minutes Per Week of Self-reported Physical Activity

    Self-reported physical activity in minutes per week of at least moderate exercise

    Time frame: 6 months

  10. Self-reported Sleep Duration

    Time frame: 6 months

06

Results

Posted Apr 15, 2022

Participant flow

Participant flow — Overall Study
MilestoneHypertension Coaching Application and Home MonitorTracking Application and Home Monitor
Started166167
Completed144152
Not completed2215
Withdrew: Lost to follow-up2215

Outcome measures

PrimaryBlood Pressure at 6 Months
Time frame:
6 months
Reported as:
Mean · mmHG
Blood Pressure at 6 Months
mmHGControlIntervention
Systolic BP135.0 ± 13.9132.3 ± 15.0
Diastolic BP85.6 ± 9.885.1 ± 9.6
PrimaryBlood Pressure <140/90mmHg
Time frame:
6 months
Reported as:
Count of participants · Participants
Blood Pressure <140/90mmHg
ParticipantsControlIntervention
Blood Pressure <140/90mmHg7278
SecondaryNumber of Antihypertensive Agents Used

Number of self reported antihypertensive medication drug classes taken

Time frame:
6 months
Reported as:
Mean · Antihypertensives
Number of Antihypertensive Agents Used
AntihypertensivesInterventionControl
Number of Antihypertensive Agents Used1.3 ± 1.01.3 ± 1.2
SecondaryAntihypertensive Medication Intensification, No. of Additions, Dose Increases, or Substitutions

Number of antihypertensive drug classes that were increased, added or substituted for another drug class

Time frame:
6 months
Reported as:
Mean · Antihypertensives
Antihypertensive Medication Intensification, No. of Additions, Dose Increases, or Substitutions
AntihypertensivesInterventionControl
Antihypertensive Medication Intensification, No. of Additions, Dose Increases, or Substitutions0.3 ± 0.60.4 ± 0.8
SecondaryNumber of Health System Contacts (Telephone, Office, or Mychart Encounters)
Time frame:
6 months
Reported as:
Mean · calls
Number of Health System Contacts (Telephone, Office, or Mychart Encounters)
callsInterventionControl
Number of Health System Contacts (Telephone, Office, or Mychart Encounters)7.0 ± 11.56.7 ± 6.5
SecondaryFrequency of Home Blood Pressure Measurements Per Month

Frequency of home blood pressure measurements per month derived from home blood pressure monitor for months when home monitoring occurred

Time frame:
6 months
Reported as:
Median · measurements per month
Frequency of Home Blood Pressure Measurements Per Month
measurements per monthInterventionControl
Frequency of Home Blood Pressure Measurements Per Month16 (8.5 to 29)17 (9 to 32.5)
SecondaryMonths When a Home Blood Pressure Reading is Obtained, No.

Number of months out of the 6 month study period when at least one home blood pressure reading was obtained

Time frame:
6 months
Reported as:
Mean · Months
Months When a Home Blood Pressure Reading is Obtained, No.
MonthsInterventionControl
Months When a Home Blood Pressure Reading is Obtained, No.4.9 ± 1.85.0 ± 1.8
SecondarySelf-efficacy: Confidence in Controlling High Blood Pressure

Self reported response to :How confident are you that you will be able to get your blood pressure controlled and keep it there during the next few months? Reponses were on a 5-point scale ranging from (1) not at all confident to (5) extremely confident.

Time frame:
6 months
Reported as:
Mean · units on a scale
Self-efficacy: Confidence in Controlling High Blood Pressure
units on a scaleInterventionControl
Confidence in controlling blood pressure4.4 ± 0.84.1 ± 0.9
Confidence in using home monitor4.8 ± 0.64.7 ± 0.7
Confidence in judging when medication change needed4.0 ± 1.34.0 ± 1.2
Confidence in doing nonmedication behaviors to control blood pressure4.4 ± 0.94.4 ± 0.9
SecondaryBMI

Body mass index is calculated as the weight in kilograms divided by height in meters squared.

Time frame:
6 months
Reported as:
Mean · kg/m^2
BMI
kg/m^2InterventionControl
BMI32.0 ± 8.231.9 ± 7.7
SecondaryDiet Quality Score (as Assessed by Dietary Approaches to Stop Hypertension Questionnaire, DASH-Q

Sum of responses represents intake of foods associated with the Dietary Approaches to Stop Hypertension diet. Range is from 0 to 77 with a higher score indicating better diet. Scores 32 and below indicate a low-quality diet, scores 33 to 51 indicate a medium-quality diet, and scores greater than or equal to 52 indicate a high-quality diet.

Time frame:
6 months
Reported as:
Mean · scores on a scale
Diet Quality Score (as Assessed by Dietary Approaches to Stop Hypertension Questionnaire, DASH-Q
scores on a scaleInterventionControl
Dietary Approaches to Stop Hypertension-Questionnaire score38.7 ± 12.139.3 ± 11.8
Consumption of processed meats, d/wk1.3 ± 1.61.5 ± 1.8
Consumption of fried foods, d/wk1.0 ± 1.31.1 ± 1.4
Consumption of sugar-sweetened beverages, d/wk1.7 ± 2.51.7 ± 2.4
Consumption of candy, baked goods, or ice cream, d/wk2.9 ± 2.32.9 ± 2.2
SecondaryMinutes Per Week of Self-reported Physical Activity

Self-reported physical activity in minutes per week of at least moderate exercise

Time frame:
6 months
Reported as:
Mean · minutes/week
Minutes Per Week of Self-reported Physical Activity
minutes/weekInterventionControl
Minutes Per Week of Self-reported Physical Activity177.6 ± 169.2143.1 ± 156.4
SecondarySelf-reported Sleep Duration
Time frame:
6 months
Reported as:
Mean · sleep hours
Self-reported Sleep Duration
sleep hoursInterventionControl
Self-reported Sleep Duration6.6 ± 1.46.5 ± 1.2

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention0/166 (0%)0/166 (0%)0/166 (0%)
Control0/167 (0%)0/167 (0%)0/167 (0%)

Baseline characteristics

166 participants contributed data for the hypertension coaching application arm of the study. 167 participants from the tracking application arm contributed data to the study. Overall number of participants is 333. 22 participants from intervention arm were excluded from analyses for various reasons leaving 144 participants for analyses.1 missing data and 14 participants were lost to follow up and were excluded from analyses in the control arm which leaves us with 153 participants for analyses.

Age, Continuous
Age, Continuous(years)Hypertension Coaching Application and Home MonitorTracking Application and Home MonitorTotal
Mean59.6 ± 12.458.3 ± 13.258.9 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Hypertension Coaching Application and Home MonitorTracking Application and Home MonitorTotal
Female9191182
Male5361114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Hypertension Coaching Application and Home MonitorTracking Application and Home MonitorTotal
Hispanic or Latino101323
Not Hispanic or Latino134139273
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Hypertension Coaching Application and Home MonitorTracking Application and Home MonitorTotal
American Indian or Alaska Native000
Asian4913
Native Hawaiian or Other Pacific Islander000
Black or African American5647103
White7379152
More than one race111728
Unknown or Not Reported000
Education
Education(Participants)Hypertension Coaching Application and Home MonitorTracking Application and Home MonitorTotal
Less thank HS graduate325
Grade 12 or GED101626
College 1-3y272855
College≥4103106209
Unknown101
Primary Language
Primary Language(Participants)Hypertension Coaching Application and Home MonitorTracking Application and Home MonitorTotal
English141143284
Other3811
Refused011
No. of antihypertensive agents used
No. of antihypertensive agents used(Participants)Hypertension Coaching Application and Home MonitorTracking Application and Home MonitorTotal
0345387
16144105
2354075
≥3141529
Body mass index
Body mass index(kg/m^2)Hypertension Coaching Application and Home MonitorTracking Application and Home MonitorTotal
Mean31.9 ± 8.331.7 ± 7.831.8 ± 8.0
07

Study locations

1 site
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
08

References and documents

Publications

  • Persell SD, Peprah YA, Lipiszko D, Lee JY, Li JJ, Ciolino JD, Karmali KN, Sato H. Effect of Home Blood Pressure Monitoring via a Smartphone Hypertension Coaching Application or Tracking Application on Adults With Uncontrolled Hypertension: A Randomized Clinical Trial. JAMA Netw Open. 2020 Mar 2;3(3):e200255. doi: 10.1001/jamanetworkopen.2020.0255. PubMed 32119093 ↗

Study documents

  • Protocol and statistical analysis plan · Jan 25, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03288142
Lead sponsor
Northwestern University
Collaborators
Omron Healthcare Co., Ltd.
Responsible party
Stephen Persell, MD, MPH (Associate Professor of Medicine, Northwestern University) — Principal investigator
First posted
Sep 19, 2017
Start date
Sep 21, 2017
Primary completion
Apr 28, 2019
Completion
Dec 1, 2019
Results posted
Apr 15, 2022
Last update
Apr 15, 2022

Study contacts

Stephen D Persell, MD/MPH
principal investigator · Northwestern Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion